Aprea Therapeutics

Contributing Author

Recent Articles by Aprea Therapeutics

Oct-24	Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 APRE GlobeNewswire
Oct-15	Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies APRE GlobeNewswire
Oct-14	Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics APRE GlobeNewswire
Aug-28	Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference APRE GlobeNewswire
Aug-12	Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update APRE GlobeNewswire
Jun-25	Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center APRE GlobeNewswire
May-14	Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update APRE GlobeNewswire